Exclusive Videos

Exclusive Videos


ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients

Sunday, January 1st, 2017
Mark J. Levis, MD, PhD, discusses the results of a phase I/II trial of ASP2215, which was shown to potently, selectively, and sustainably inhibit...

Ruxolitinib in CMML: Study Shows Promising Results

Monday, October 31st, 2016
Eric Padron, MD, shares results from the phase I study of ruxolitinib in chronic myelomonocytic leukemia, a rare type of myelodysplastic, myeloproliferative neoplasm with...

Options for Treating the High-Risk APL Patient

Sunday, June 5th, 2016
Alan Burnett, MD, takes a look at the combination of ATRA + ATO + GO in high-risk acute promyelocytic leukemia (APL) patients, the complications...

PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape

Thursday, April 21st, 2016
Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more...

SIRIUS: Promising Results for Daratumumab in Hard-to-Treat Myeloma Patients

Friday, March 20th, 2015
Saad Zafar Usmani, MD, shares the “unprecedented” results from the phase II trial of the anti-CD38 monoclonal antibody daratumumab in patients with double refractory...

Current Issue

April 2017, Volume 3, Issue 5

This issue examines the art and science of myeloma drug sequencing, Mikkael Sekeres' letter to the ABIM, highlights from the 16th International Myeloma Workshop, and more.